The U.S. deprescribing research network: Catalyzing research and action to optimize medication use in older adults.
作者信息
Boyd Cynthia M, Steinman Michael A
机构信息
Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Division of Geriatrics, University of California San Francisco and the San Francisco VA Medical Center, San Francisco, California, USA.
出版信息
J Am Geriatr Soc. 2024 May;72(5):1611-1613. doi: 10.1111/jgs.18856. Epub 2024 Mar 8.
Abstract
摘要
相似文献
1
The U.S. deprescribing research network: Catalyzing research and action to optimize medication use in older adults.美国减药研究网络：推动优化老年人用药的研究与行动。
J Am Geriatr Soc. 2024 May;72(5):1611-1613. doi: 10.1111/jgs.18856. Epub 2024 Mar 8.
2
Polypharmacy and Deprescribing in Older Adults.老年人的多种药物治疗和减药。
Annu Rev Med. 2024 Jan 29;75:113-127. doi: 10.1146/annurev-med-070822-101947. Epub 2023 Sep 20.
3
The Role of Deprescribing in Older Adults with Chronic Kidney Disease.减药在老年慢性肾脏病患者中的作用
Drugs Aging. 2018 Nov;35(11):973-984. doi: 10.1007/s40266-018-0593-8.
4
Optimizing pharmacotherapy and deprescribing strategies in older adults living with multimorbidity and polypharmacy: EuGMS SIG on pharmacology position paper.优化患有多种疾病和多种药物治疗的老年患者的药物治疗和减药策略：EuGMS 药理学工作组关于立场文件的建议。
Eur Geriatr Med. 2023 Dec;14(6):1195-1209. doi: 10.1007/s41999-023-00872-0. Epub 2023 Oct 9.
5
The value of deprescribing in older adults with dementia: a narrative review.老年痴呆症患者药物减量的价值：叙事性综述。
Expert Rev Clin Pharmacol. 2021 Nov;14(11):1367-1382. doi: 10.1080/17512433.2021.1961576. Epub 2021 Aug 19.
6
What do older adults with multimorbidity and polypharmacy think about deprescribing? The LESS study - a primary care-based survey.患有多种合并症和多种药物治疗的老年人对减少药物治疗有何看法？LESS 研究 - 基于初级保健的调查。
BMC Geriatr. 2020 Oct 31;20(1):435. doi: 10.1186/s12877-020-01843-x.
7
Harm and Medication-Type Impact Agreement with Hypothetical Deprescribing Recommendations: a Vignette-Based Experiment with Older Adults Across Four Countries.与假设的减药建议相关的危害和药物类型影响协议：基于四个国家的老年人案例的实验。
J Gen Intern Med. 2023 May;38(6):1439-1448. doi: 10.1007/s11606-022-07850-5. Epub 2022 Nov 14.
8
Enhancing older Veterans' care: Insights from medication reviews and deprescribing interventions.加强老年退伍军人的护理：药物审查和减药干预的见解。
Res Social Adm Pharm. 2025 Jan;21(1):32-40. doi: 10.1016/j.sapharm.2024.09.006. Epub 2024 Sep 25.
9
Medication review and deprescribing in different healthcare settings: a position statement from an Italian scientific consortium.在不同医疗环境下的药物审查和药物精简：来自意大利科学联盟的立场声明。
Aging Clin Exp Res. 2024 Mar 8;36(1):63. doi: 10.1007/s40520-023-02679-2.
10
Pharmacists' attitudes towards interprofessional collaboration to optimise medication use in older patients in Switzerland: a survey study.瑞士药剂师对优化老年患者用药的跨专业合作态度：一项调查研究。
BMC Health Serv Res. 2024 Jul 26;24(1):849. doi: 10.1186/s12913-024-11339-8.
引用本文的文献
1
Happy 50th birthday to the National Institute on Aging: Where would geriatric medicine and care of older adults be without you?祝美国国立衰老研究所成立50周年生日快乐：没有你们，老年医学和老年人护理将会怎样？
J Am Geriatr Soc. 2024 May;72(5):1570-1573. doi: 10.1111/jgs.18931. Epub 2024 Apr 25.
本文引用的文献
1
Defining key deprescribing measures from electronic health data: A multisite data harmonization project.从电子健康数据中定义关键的减药措施：一个多站点数据协调项目。
J Am Geriatr Soc. 2025 Feb;73(2):399-410. doi: 10.1111/jgs.19280. Epub 2024 Nov 28.
2
Deprescribing medications among patients with multiple prescribers: A socioecological model.多位处方医生的患者中药物减量：一个社会生态学模型。
J Am Geriatr Soc. 2024 Mar;72(3):660-669. doi: 10.1111/jgs.18667. Epub 2023 Nov 9.
3
Partnering with a stakeholder steering group to co-design the PRIME deprescribing conversation tool: Reflections and recommendations.与利益相关者指导小组合作共同设计PRIME减药对话工具：反思与建议。
Basic Clin Pharmacol Toxicol. 2024 Jan;134(1):121-125. doi: 10.1111/bcpt.13938. Epub 2023 Sep 8.
4
Identifying barriers and facilitators to deprescribing benzodiazepines and sedative hypnotics in the hospital setting using the Theoretical Domains Framework and the Capability, Opportunity, Motivation and Behaviour (COM-B) Model: a qualitative study.使用理论领域框架和能力、机会、动机和行为（COM-B）模型识别医院环境中减少苯二氮䓬类药物和镇静催眠药使用的障碍和促进因素：一项定性研究。
BMJ Open. 2023 Feb 22;13(2):e066234. doi: 10.1136/bmjopen-2022-066234.
5
Value assessment of deprescribing interventions: Suggestions for improvement.减药干预措施的价值评估：改进建议。
J Am Geriatr Soc. 2023 Jun;71(6):2023-2027. doi: 10.1111/jgs.18298. Epub 2023 Feb 21.
6
Recommendations for outcome measurement for deprescribing intervention studies.药物减量干预研究结局指标的推荐意见。
J Am Geriatr Soc. 2022 Sep;70(9):2487-2497. doi: 10.1111/jgs.17894. Epub 2022 Jun 1.
7
Deprescribing and deimplementation: Time for transformative change.减药与停用：变革性改变的时刻已至。
J Am Geriatr Soc. 2021 Dec;69(12):3693-3695. doi: 10.1111/jgs.17441. Epub 2021 Sep 9.
8
Outcome Measures for Interventions to Reduce Inappropriate Chronic Drugs: A Narrative Review.干预措施减少不合理慢性药物使用的结局指标：叙事性综述。
J Am Geriatr Soc. 2020 Oct;68(10):2390-2398. doi: 10.1111/jgs.16697. Epub 2020 Aug 11.
9
Deprescribing: the emerging evidence for and the practice of the 'geriatrician's salute'.撤药：“老年病医生敬礼”的新兴证据和实践。
Age Ageing. 2018 Sep 1;47(5):638-640. doi: 10.1093/ageing/afy014.
10
A realist evaluation of patients' decisions to deprescribe in the EMPOWER trial.在“增强能力”试验中对患者减药决策的现实主义评价。
BMJ Open. 2017 May 4;7(4):e015959. doi: 10.1136/bmjopen-2017-015959.
Zotero 插件